Notice to grant from EPO on Attana patent application

Attana has today received a notice of intention to grant from the European Patent Office (EPO). The formal grant will follow shortly. Corresponding patents have previously been granted in the USA and Japan

 ​Attana has today received a notice of intention to grant European patent application no. 04710140.7. Corresponding patents have previously been granted in the USA and Japan.  The European patent application should be granted shortly. Once granted by the EPO Attana will validate the patent in a number of key European countries.

The invention is relates to improving the sensitive of the core technology in Attana’s biosensors.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com 
tel: + 46 8 674 57 00

This is information that Attana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at May 7 CET on 21.50 2018

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences.  To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact  sales@attana.com.